All News

lung%2Cbright.jpg

Increased Risk of COPD in ACPA+ Pre-RA Patients

d Jack Cush, MD

The lung and its pathology is uniquely tied to rheumatoid arthritis (RA) and its pathogenesis.  A new study shows that elevation of anti–citrullinated protein antibodies (ACPAs) before diagnosis of RA increases the risk of developing chronic obstructive pulmonary disease (COPD

Read Article
shingles2.jpg

New Side Effect From mRNA COVID Vaccines?

d MedPage Today

Herpes zoster reactivation -- a.k.a. shingles -- following COVID-19 vaccination in six patients with comorbid autoimmune/inflammatory diseases may be a new adverse event associated with the Pfizer/BioNTech mRNA vaccine, suggested a new report.

Read Article
Raynaud-hand2.jpg

Raynaud and Microvascular Complications with New Migraine Meds

d Jack Cush, MD

A new study of calcitonin gene-related peptide (CGRP) antagonists for migraine headaches found that a small subset manifested Raynaud phenomenon and other had microvascular complications, suggesting that CGRP antagonists should be used in caution in patients with Raynauds. 

Read Article
37 RA, 28 PsA & 20 AS pts in remission/LDA x 6 mos enrolled in DMARD spacing. Joint flares seen in 13.5% RA, 21.4% PsA & 20% axSpA pts but 5 more PsA patients had skin flare. PsA had lower persistence 61% (vs RA 87% & 80% AS) due to skin flares https://t.co/d1rMLTXSQs https://t.co/fNNSofWxgv

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Dr. Charles Christian of HSS Honored In the current issue of Annals of Rheumatic Disease, Dr. Peggy Crow honors the life and career of one the great, historic rheumatologists of all time: Dr. Charles Christian. https://t.co/UYOcR0QPc4 https://t.co/ML4snlVumB

Links:

Dr. John Cush RheumNow ( View Tweet)
55 pts w/ Multi-joint osteonecrosis (>2 jts).( SLE 29%, ALL 11%, HIV 9%, EtOH 4%). Mean cumulative steroid dose >30 g over 5 yrs. Predictors of MJON was cumulative oral steroid dose (3.2% incr per 1000 mg. MJON risk incr 12 X w/ 2nd risk factor https://t.co/dqTPh2PV8V https://t.co/HTrSnZSefK

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 207 Pediatric pts treated w/ Rituxan (for Rheum, Cancer, CNS, Renal dz) and 40% developed hypogammaglobulinemia post-RTX; hypo-IgG Pre-RTX 28.7% to Post RTX 42.6%, p=0.009; low IgG levels had higher risk of serious infx (OR 2.3) https://t.co/b91rPYgVV2

Links:

Dr. John Cush RheumNow ( View Tweet)

A Patient-Centered Exploration of Axial Involvement in SpA Sponsored by Novartis Medical Affairs Listen to a medical expert differentiate axial involvement within the spectrum of spondyloarthritis. https://t.co/o2q5pTP3WD https://t.co/GiqdIqitMB

Links:

Dr. John Cush RheumNow ( View Tweet)
Great reminder of from Dr. Kathryn Dao, @KDAO2011 from #RNL2021 Caution! Verrucous LE can simulate skin cancer! Both can be found in photosensitivity areas! #RheumNow

Dr. John Cush RheumNow ( View Tweet)

Shared from #RNL2021 from @uptoTate "Absence of proof of an effect is not proof of absence of an effect!" Dr. Kavanaugh's sage reminder for the day"

Dr. John Cush RheumNow ( View Tweet)

Tonight! Join us for Tuesday Night Rheumatology with Dr. Philip Robinson and Dr. Iain McInness. We'll discuss highlight sessions for RheumNow Live 2021 #RNL2021 https://t.co/oJ4xYKLrj4 https://t.co/K1OQz40aZ1

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Planes, Trains and COVID Distancing MMWR reports the risk of acquiring an infection with SARS-CoV-2 is reduced 23% to 57% when the middle seat was vacant (compared with full aircraft occupancy). https://t.co/tGs9GopeGu https://t.co/ZRMltTpYgW

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Broadalumab Efficacy in Axial Spondyloarthritis Broadalumab, an anti-interleukin-17 receptor A monoclonal antibody, is FDA- approved for use in adults with plaque psoriasis; but a recent trial shows it to be effective in patients with axSpA. https://t.co/V0zKbFMgy7 https://t.co/U5CGXUF7Sw

Links:

Dr. John Cush RheumNow ( View Tweet)
Dual seropositivity with RF/ACPA autoantibody higher titers were strongly associated with prevalent RA-ILD (OR 2.90; developed in 3.7%). ILD more likely with high titer RF (HR 3.4) than high titer CCP (HR 1.9). https://t.co/ebvJjatQSw

Links:

Dr. John Cush RheumNow ( View Tweet)

304 pts w/ Knee OA studied by MRI and atorvastatin 40 mg qd was no better than placebo in reducing cartilage volume loss, BM lesions, pain, or function over 2 years https://t.co/MIdIFQ9qzs

Links:

Dr. John Cush RheumNow ( View Tweet)

Serious problem! Pulmonologists uniformly believe that MTX causes and/or worsens ILD. MTX causes hypersensitivity pneumonitis, not ILD. RA, lupus DM, PSS cause ILD and they may need MTX to manage their disease. Do your own research, look at this paper to start. https://t.co/DHC5ikhCf6

Links:

Dr. John Cush RheumNow ( View Tweet)

There's a special, deep hell for insurers/PBM's that give patients a hassle over paying for a cheap drug like methotrexate. And these days it's looking like it's going to be very, very crowded.

Ethan Craig rheumecraig ( View Tweet)

Another @preventiveneur1 paper just published. @tomrptaylor looked at demyelinating events reported in people taking anti-TNF in the BSRBR. We found that these events are uncommon in people with underlying rheumatological disease https://t.co/qCaF6YMLAh

Links:

Ruth Dobson drruthdobson ( View Tweet)

#RNL2021 coverage from @doctorRBC "Biosimilars are on their way. Coming to you in 2024! They will most likely be cheaper for insurance companies, but will they be cheaper for patients? " #RheumNow

Dr. John Cush RheumNow ( View Tweet)

Join us for Tuesday Night Rheumatology with Dr. Philip Robinson and Dr. Iain McInness. We'll discuss highlight sessions for RheumNow Live 2021 #RNL2021 https://t.co/oJ4xYL32aC https://t.co/Eix01GlWoj

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×